RxDoctor Payments Data

Jill Glick, DO

Family Medicine · Kaufman, TXNPI 1851351589

Payments from drug & device makers

$7,562in general payments, 2019–2025

Across 373 payments — averaging $20.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$885
  • Medtronic$867
  • AstraZeneca$408
  • Amarin Pharma, Inc.$385
  • Astellas Pharma US Inc$374
  • plus $3K from 38 others

What the payments were for

  • Travel & lodging$72510%
  • Food & beverage$6,83890%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,562 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$14,656
Medicare patients
50
Services billed
181

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron19$25,294
TrulicityDulaglutide21$24,703
VraylarCariprazine Hcl11$18,522
EliquisApixaban12$14,376
OzempicSemaglutide12$14,372
JanumetSitagliptin Phos/Metformin Hcl11$13,966
FarxigaDapagliflozin Propanediol21$13,327
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$13,061
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$12,798
Risedronate Sodium19$2,189
Gabapentin80$1,978
Methocarbamol21$1,310
Roflumilast11$1,043
Esomeprazole Magnesium25$991
Escitalopram Oxalate74$955

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$408$26,12537 claims
Astellas Pharma US IncMyrbetriq$374$25,29419 claims
Lilly USA, LLCTrulicity$322$24,70321 claims
AbbVieVraylar$1,409$18,52211 claims
PfizerEliquis$366$14,37612 claims
Novo NordiskOzempic$885$14,37212 claims
MerckJanumet$96$13,96611 claims
GSKTrelegy Ellipta$177$13,06112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Kaufman

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →